dismiss

Come visit us at Booth 901 at AHRMM in Washington, DC
Mark your calendars! On August 2nd is our upcoming LIVE Clean Sweep Auction

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

 

More Industry Headlines

Henry Ford Cancer Institute treats first patient with ViewRay's MRIdian Linac 'Takes off the blindfold' for radiation oncologists

Philips and West Physics partner on CT dose management program Deal aims at helping providers meet dose management needs

Taking the bite out of rabies In 1885 Louis Pasteur successfully tested his rabies vaccine

Research team develops surgical glue that's visible with CT, X-ray and ultrasound Viable alternative to surgical staples

Medic Vision receives U.S. patent for XR-29 Dose-Check system 'Fully expects' imaging service providers to respect its patent rights

GE Healthcare, Jefferson Health partner for $1 billion in efficiencies Eight-year deal will put over 100 GE staffers into 13 network hospitals

ECRI launches its ValuVu product evaluation workflow platform Designed for supply chain and value analysis professionals

PET scans could improve dementia diagnosis in two-thirds of patients 'A swift and accurate diagnosis has a huge impact on access to Alzheimer's treatments.'

Mayo launches new $1.5 billion integrated Epic EHR system Customized to 'specific needs of Mayo Clinic patients and staff'

Philips acquires ultrasound software company TomTec Third deal in the past thirty days

Blood test may beat
imaging in cancer prediction

Blood test could detect lung cancer up to five years before CT scans

by Brendon Nafziger , DOTmed News Associate Editor
A blood test could detect about half of lung cancers up to five years before other tests, according to a team of British scientists.

In a series of papers to be presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago, the scientists from the company Oncimmune tout their "Early CDT-Lung Test" for finding around 40 percent of lung cancers years before they show up on CT scans.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



The company hopes the test, commercially available in the United States starting Tuesday, will not only save lives by detecting cancer early, but drive down health care costs.

The test works by looking for antibodies, called auto-antibodies, which the body produces to combat cancer.

As Geoffrey Hamilton-Fairley, executive chairman of Oncimmune, explained to DOTmed News, cancer cells divide rapidly. During division, they release antigens that the body recognizes as foreign, which it combats with auto-antibodies.

"Everybody has a background count of these auto-antibodies," Hamilton-Fairley said, which actually increase as we age, possibly because our bodies are fighting off many less aggressive cancers successfully.

The research originated with John Robertson, a professor at the University of Nottingham. As part of their yearly check-up, his patients at high-risk for breast cancer had their blood drawn. If they came down with cancer, Robertson went back to their blood samples and retroactively tested them for the auto-antibodies, finding that over half of the cancers could have been found four years before diagnosis.

For the current test, patients have their blood samples mailed to Oncimmune's U.S. testing facility in De Soto, Kan., just outside Kansas City.

The researchers then choose a selection of around six antigens that they pass a patient's blood sample over. If auto-antibodies are present, they'll bind to the antigens. After doing this a few times for accuracy, researchers develop the patient's antigen "fingerprint." This fingerprint is then compared against a population cut-off to judge the patient's risk for developing cancer.

Eventually, physicians will compare a patient's fingerprint against those taken from previous years, and not just population cut-offs, for more accurate readings, Hamilton-Fairley said.

"We'll end up with your own individual antigen fingerprint," he said, "and you'll be able to compare that year by year, and over time you'll pay more attention if you stray from the personal profile."

For now, they recommend one test about every five years, but as the patient ages or if there are risk factors - specifically, smoking - doctors might look at it more often.
  Pages: 1 - 2 - 3 >>

Related:


Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED